bioMérieux, Inc. Receives Nine AOAC Approvals in November

07 December, 2020

These approvals add to bioMérieux’s already vast AOAC approved portfolio across their pathogen and quality indicator suite of solutions, and demonstrates a long-standing commitment to robust, sound, and validated science.

December 7, 2020—bioMérieux, a world leader in the field of in vitro diagnostics, received nine approvals from the AOAC Research Institute Performance Tested Methodssm in November 2020.

These approvals add to bioMérieux’s already vast AOAC approved portfolio across their pathogen and quality indicator suite of solutions, and demonstrates a long-standing commitment to robust, sound, and validated science.

New approvals include:

  • GENE-UP® SLM2 (PTM 121802) Cannabis flower and whole hemp flower
  • GENE-UP® EHEC (PTM 121806) Cannabis flower and whole hemp flower
  • GENE-UP® SLM2 (PTM 121802) 375g Romaine lettuce (10 h enrichment time)
  • GENE-UP® ECO (PTM 121805) Raw ground beef (375 g in mTSB)
  • TEMPO® CAM (PTM 112002) Raw ground chicken (325 g), raw chicken livers (325 g), chicken carcass rinses (30 mL), raw ground turkey (25 g) and turkey carcass sponges
  • Group Modification:​
    • GENE-UP® PMAXX - LIS2 (PTM 121803) Addition of an extracellular DNA removal step
    • GENE-UP® PMAXX - LMO2 (PTM 121805) Addition of an extracellular DNA removal step
    • GENE-UP® PMAXX - SLM2 (PTM 121802) Addition of an extracellular DNA removal step
    • GENE-UP® PMAXX - CRO (PTM 081801) Addition of an extracellular DNA removal step

In particular, the cannabis and whole hemp flower approvals mark a historic milestone.

“We are especially proud that the GENE-UP SLM2 and EHEC are the first two AOAC approvals in the US for cannabis and hemp,” said Stan Bailey, Senior Director of Scientific Affairs at bioMérieux, Inc. “This is increasingly important with now over half the population of the US in states that have approved cannabis for recreational use and even more states approving cannabis for medical use.”

In addition to the matrix extensions, bioMérieux, Inc. now offers an optional DNA removal step for customers with a high bioburden load of dead pathogens. This step allows customers to focus on real problems and eliminate background noise from dead pathogen DNA. Adding BACTVIAB™ PMAxx™ removes extracellular DNA without impacting the performance of GENE-UP assays.

The new AOAC validations bring value to the food safety and quality industry.

"AOAC provides confidence in independent, uniformly validated rapid test methods for evaluating the quality and safety of the global food supply,” said Ron Johnson, Sr. Scientific Affairs Advisor at bioMérieux, Inc. and Former President of AOAC (Sept. 2016 - Sept. 2017). “I’m very proud and grateful for bioMérieux’s foresight and commitment to analytical excellence in global food safety and public health."

Visit AOAC’s website to learn more about their validation process and explore our website to learn more about our suite of food safety and quality solutions

ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2019, revenues reached €2.7 billion, with over 90% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

Contacts

bioMérieux, Inc.

Joy Dell'aringa 224.213.1756
joy.dellaringa@biomerieux.com

bioMérieux Corporate Industry Head Office 

Olivia Seward +33 (0) 668740207
olivia.seward@biomerieux.com

Pioneering Diagnostics